More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$102.92B
EPS
1.52
P/E ratio
12.5
Price to sales
1.72
Dividend yield
3.585%
Beta
0.455851
Previous close
$50.45
Today's open
$51.23
Day's range
$50.38 - $51.43
52 week range
$45.81 - $61.70
CEO
Luke Miels
Employees
68629
Headquarters
London,
Exchange
New York Stock Exchange
Shares outstanding
2.02B
Issue type
American Depository Receipt
Healthcare
Pharmaceuticals
FDA grants accelerated approval to GSK's lung cancer drug
FDA grants accelerated approval to GSK's lung cancer drug
Reuters • 2 hours ago

GSK: 3 Key Takeaways for Long-Term Investors
GSK started 18 phase 3 clinical trials in 2026. Specialty medicine sales grew 15% in the third quarter.
The Motley Fool • 15 hours ago

GSK Targets £40 Billion in Sales as HIV Patent Cliff Looms
GSK NYSE: GSK expects to grow through the loss of patent protection for key HIV medicines, relying on a pipeline of new treatments, an expanding oncology business and continued dealmaking, President of Business Development David Redfern said at the Jefferies Healthcare Conference.
MarketBeat • 9 hours ago

GSK Accelerates Late-Stage Studies as It Targets COPD and Long-Acting Respiratory Treatments
GSK NYSE: GSK is advancing a portfolio of long-acting medicines and combination treatments for respiratory and inflammatory diseases, with a particular focus on chronic obstructive pulmonary disease, a senior research executive said at Guggenheim's Healthcare Innovation Conference.
MarketBeat • Nov 9, 2026

GSK, Moderna settle patent dispute over Moderna COVID, RSV shots
British drugmaker GSK has settled lawsuits that accused Moderna's [COVID-19 vaccines Spikevax and mNEXSPIKE and RSV shot mResvia of infringing its patents, the companies said on Friday.
Reuters • Nov 6, 2026

Alamar Biosciences Partners with GSK on Large-Scale Proteomic Study to Advance Precision Medicine
FREMONT, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced a strategic scientific collaboration with GSK plc (LSE/NYSE: GSK) that will use Alamar's NULISA™ platform in a large-scale study examining how circulating protein signatures relate to disease progression, biological subtypes and treatment response across respiratory, liver, kidney, neurological and autoimmune conditions.
GlobeNewsWire • Nov 3, 2026

GSK: The Gas Pedal Is Still Down, But Bumps Ahead
Despite the Q3 disappointments, I maintain my Buy rating, as strong Specialty Medicines growth and improving pipeline momentum continue to support GSK's long-term ambitions. Specialty Medicines revenue rose 14%, helping offset weakness in Vaccines. HIV, Oncology and Respiratory remain key drivers of GSK's future growth. The vaccine business underperformed, with Shingrix and Arexvy missing expectations; management attributes this to China inventory reductions and broader RSV demand issues.
Seeking Alpha • Oct 30, 2026

GSK vs. Moderna: Which Large-Cap Biotech Stock Offers More Growth?
GSK's Specialty Medicines growth, deep pipeline and dividend offer a compelling case against MRNA's oncology potential and premium valuation.
Zacks Investment Research • Oct 29, 2026

GSK beats third-quarter profit estimates, keeps annual targets
GSK beat third-quarter sales and profit expectations on Wednesday, driven by demand for specialty medicines after the drugmaker began a strategic overhaul under CEO Luke Miels to accelerate growth and prepare for looming patent losses.
Reuters • Oct 28, 2026

GSK's Specialty Drugs Grow by Double Digits While Vaccines Slip in a Q3 Beat
GSK Plc (NYSE:GSK) reported third-quarter adjusted earnings of $1.47 per share (54.6 pence), beating the analyst consensus estimate of $1.40.
Benzinga • Oct 28, 2026

¹ Disclosures

Open an M1 investment account to buy and sell GSK plc American Depositary Shares (Each representing two) commission-free¹. Build wealth for the long term using automated trading and transfers.